Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : EntreMed (ENMD) -- Ignore unavailable to you. Want to Upgrade?

To: Matthew Tyson who wrote (1805)	3/4/1999 3:31:00 PM
From: Anthony@Pacific	Read Replies (1) \| Respond to of 2135

ENMD<--------DECIEVES THE PUBLIC in an attempt to con the public into thinking they are working WITH Covance ..when in reality they hired Covance to do job that Bristol Myers refused to FUND!!!! PACIFIC INVESTIGATIONS RATES ENMD AN IMMEDIATE SELL/SHORT! March 3, 1999 To All Business Editors FOR IMMEDIATE RELEASE SAN DIEGO, CA "PACIFIC INVESTIGATIONS RATES ENMD AN IMMEDIATE SELL/SHORT! Pacific Investigations lead corporate and equity analyst, Anthony Elgindy, initiates coverage on ENTREMED symbol "ENMD" with an IMMEDIATE SELL/SHORT RECOMMENDATION!" @ 21 PLUS In a tape-recorded interview this morning with Entremed employees, Pacific Investigations has learned that the wording in yesterdays press release was intentionally misleading… Covance was contracted by ENMD to produce Angiostatin and Endostatin FOR ENMD and did not replace Bristol Myers, in their Role as was alluded to in the press release Covance is not a partner nor is COVANCE participating in bearing any of the costs of these two compounds.. This was a simply a contract initiated by ENMD and Covance has no participation in the ultimate use or lack of use of these Compounds.. It is clear to the investigators at Pacific that there is no economical viability for these compound and no revenues will be realized for at least 3 to 5 years from this point, and as such all these press releases and the various articles by ENMD are premature at best and self promotional to say the least.. ENMD is expected to have mounting losses and without Bristol Myers it is becoming clear that not only is ENMD grossly overvalued but may actually never have any economic value whatsoever! We currently believe shareholders of ENMD should sell their shares and we are also recommending the sale of ENMD shares short. Pacific Investigations, it's officers, employees or customers may have a long or short position and this position can and does change without prior notice. Pacific Investigations 2611 South Highway 101 Suite 100 Cardiff by the Sea, California Contact: Anthony Elgindy 619-756-5375 619-756-5381 FAX